Development of an in-vivo active reversible butyrylcholinesterase inhibitor

Citations Over TimeTop 10% of 2016 papers

Abstract

Alzheimer's disease (AD) is characterized by severe basal forebrain cholinergic deficit, which results in progressive and chronic deterioration of memory and cognitive functions. Similar to acetylcholinesterase, butyrylcholinesterase (BChE) contributes to the termination of cholinergic neurotransmission. Its enzymatic activity increases with the disease progression, thus classifying BChE as a viable therapeutic target in advanced AD. Potent, selective and reversible human BChE inhibitors were developed. The solved crystal structure of human BChE in complex with the most potent inhibitor reveals its binding mode and provides the molecular basis of its low nanomolar potency. Additionally, this compound is noncytotoxic and has neuroprotective properties. Furthermore, this inhibitor moderately crosses the blood-brain barrier and improves memory, cognitive functions and learning abilities of mice in a model of the cholinergic deficit that characterizes AD, without producing acute cholinergic adverse effects. Our study provides an advanced lead compound for developing drugs for alleviating symptoms caused by cholinergic hypofunction in advanced AD.

Related Papers

• → Synthesis and In Vitro Evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a Cholinesterase Inhibitor with Regard to Alzheimer's Disease Treatment(2010)23 cited
• → Biochemical Measurement of Cholinesterase Activity(2003)33 cited
• → The role of cholinesterases in chagas disease(2022)3 cited
• → A Comparison of Blood Cholinesterase Activities, Pyridostigmine Inhibition of Red Cell Acetylcholinesterase, and Butyrylcholinesterase Phenotypes in Gulf War Veterans and Normal Controls(1998)
• Analysis of cholinesterases activity and their variation in rat serum upon repeated exposure to chlorpyrifos(2014)